# TNIP3

## Overview
TNIP3, or TNFAIP3 interacting protein 3, is a gene that encodes a protein involved in the regulation of inflammatory responses and immune signaling pathways. The protein encoded by TNIP3 is a regulatory molecule that interacts with various signaling proteins, including A20 and STAT1, to modulate pathways such as NF-kB and JAK/STAT, which are critical for controlling inflammation and cell survival. TNIP3 is categorized as a regulatory protein due to its role in modulating these signaling pathways. It is active in both the cytoplasm and nucleus, influencing processes like apoptosis and immune response regulation. The protein's interactions and regulatory functions have significant implications in pathological conditions such as cardiac hypertrophy and nonalcoholic steatohepatitis (NASH), where it acts as a negative regulator by stabilizing key signaling molecules and preventing their degradation (Liu2020TNFAIP3; Shi2024TNIP3).

## Function
TNIP3, also known as TNFAIP3 interacting protein 3, plays a significant role in regulating inflammatory responses and immune signaling pathways. It interacts with the A20 protein, modulating NF-kB signaling, which is crucial for controlling inflammation and cell survival. TNIP3 is active in both the cytoplasm and nucleus, where it influences processes such as apoptosis and immune response regulation. In the context of pathological cardiac hypertrophy, TNIP3 acts as a negative regulator by stabilizing STAT1, a transcription factor involved in the JAK/STAT signaling pathway. This stabilization occurs through the inhibition of STAT1's K48-type ubiquitination, preventing its degradation and promoting its activation. This interaction enhances the transcription factor activity of STAT1 and activates its target genes under hypertrophic stress conditions, thereby protecting against cardiac hypertrophy (Shi2024TNIP3).

In healthy human cells, while specific functions of TNIP3 are not detailed in the provided context, its involvement in modulating NF-kB signaling and interaction with A20 suggests a role in maintaining cellular homeostasis and regulating immune responses. Its activity in the cytoplasm and nucleus indicates its broad influence on cellular processes related to inflammation and survival (Shi2024TNIP3).

## Clinical Significance
TNIP3 (TNFAIP3 interacting protein 3) has been implicated in several diseases due to alterations in its expression levels and interactions. In the context of nonalcoholic steatohepatitis (NASH), a severe form of fatty liver disease, TNIP3 expression is significantly downregulated. This downregulation correlates with increased hepatic steatosis, inflammation, and fibrosis, exacerbating NASH progression. Overexpression of TNIP3 in hepatocytes has been shown to suppress these symptoms by blocking TAK1 activation, suggesting its potential as a therapeutic target for NASH (Liu2020TNFAIP3).

In cardiovascular diseases, particularly pathological cardiac hypertrophy, TNIP3 acts as a negative regulator. Its expression is upregulated in response to stress, such as transverse aortic constriction (TAC) surgery in mice. TNIP3 stabilizes STAT1 by inhibiting its ubiquitination, which is crucial for preventing cardiac hypertrophy. TNIP3 deficiency leads to worsened cardiac hypertrophy, while its overexpression reverses this condition, highlighting its protective role in heart health (Shi2024TNIP3).

These findings underscore the clinical significance of TNIP3 in regulating inflammation and stress responses in liver and heart diseases, making it a promising target for therapeutic interventions.

## Interactions
TNIP3, also known as TNFAIP3 interacting protein 3, is involved in several protein interactions that influence cellular processes. In the context of cardiac hypertrophy, TNIP3 interacts with the signal transducer and activator of transcription 1 (STAT1). This interaction stabilizes STAT1 by inhibiting its K48-type ubiquitination, thereby preventing its degradation. The stabilization of STAT1 by TNIP3 is crucial for its protective role against cardiac hypertrophy (Shi2024TNIP3).

In nonalcoholic steatohepatitis (NASH), TNIP3 interacts with TAK1 (TGF-b-activated kinase 1) in hepatocytes. TNIP3 overexpression reduces TAK1 activation by preventing its ubiquitination by the E3 ligase TRIM8. This interaction inhibits downstream signaling pathways such as IKKb-NF-kB and MKK7-JNK, which are involved in hepatic steatosis, inflammation, and fibrosis (Liu2020TNFAIP3). The AHD1 domain of TNIP3 is essential for its interaction with TAK1, highlighting its potential as a therapeutic target for NASH (Liu2020TNFAIP3).

These interactions demonstrate TNIP3's role in modulating key signaling pathways through its interactions with STAT1 and TAK1, impacting conditions like cardiac hypertrophy and NASH.


## References


[1. (Liu2020TNFAIP3) Dan Liu, Peng Zhang, Junjie Zhou, Rufang Liao, Yan Che, Mao-Mao Gao, Jiaqi Sun, Jingjing Cai, Xu Cheng, Yongping Huang, Guopeng Chen, Hongyu Nie, Yan-Xiao Ji, Xiao-Jing Zhang, Zan Huang, Haibo Xu, Zhi-Gang She, and Hongliang Li. Tnfaip3 interacting protein 3 overexpression suppresses nonalcoholic steatohepatitis by blocking tak1 activation. Cell Metabolism, 31(4):726-740.e8, April 2020. URL: http://dx.doi.org/10.1016/j.cmet.2020.03.007, doi:10.1016/j.cmet.2020.03.007. This article has 72 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cmet.2020.03.007)

[2. (Shi2024TNIP3) Hongjie Shi, Yongjie Yu, Dajun Li, Kun Zhu, Xu Cheng, Tengfei Ma, Zhangqian Tao, Ying Hong, Zhen Liu, Siyi Zhou, Jianqing Zhang, Yun Chen, Xiao-Jing Zhang, Peng Zhang, and Hongliang Li. Tnip3 protects against pathological cardiac hypertrophy by stabilizing stat1. Cell Death &amp; Disease, June 2024. URL: http://dx.doi.org/10.1038/s41419-024-06805-4, doi:10.1038/s41419-024-06805-4. This article has 0 citations.](https://doi.org/10.1038/s41419-024-06805-4)